Doses of Apixaban and Rivaroxaban Prescribed in Real-World United States Cardiology Practices Compared to Registration Trials.

Doses of Apixaban and Rivaroxaban Prescribed in Real-World United States Cardiology Practices Compared to Registration Trials. Curr Med Res Opin. 2016 Mar 24;:1-13 Authors: Nguyen E, White CM, Patel MR, Fields LE, Peacock WF, Crivera C, Coleman CI Abstract Using an IMS LifeLink dataset (9/19/2014-9/11/2015), we evaluated US cardiologist prescribing of the reduced dose of apixaban (2.5 mg) or rivaroxaban (15 mg) to utilization in their corresponding nonvalvular atrial fibrillation registration randomized trials. Of all prescriptions written by cardiologists for these agents, 20.8% of apixaban and 21.7% of rivaroxaban prescriptions were for a reduced dose; corresponding to a 4.4-fold (16.1% absolute) increase in use of reduced dose apixaban and a 3% relative (0.6% absolute) increase in reduced dose rivaroxaban use vs. their respective registration trials. Further research is needed to better understand appropriate dosing of patients with novel anticoagulants. PMID: 27009372 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research